CRNX
Crinetics Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$83.87+0.01%
Price as of Jul 20, 2026
CRNX profitability
Crinetics Pharmaceuticals, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 98.9%
- EBITDA margin
- -2723.4%
- EBIT margin
- -3020.3%
- Net margin
- -2747.2%
- Free cash flow margin
- -2321.7%
Returns
- Return on equity
- -38.8%
- Return on assets
- -35.4%
- Return on invested capital
- -41.1%
- Asset turnover
- 0.01x
Cash efficiency
- Cash from operations
- -$414.2M
- Cash per share
- $12
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.